Price to Operating Profit (P/OP)
since 2005
Paying user area
Try for free
Cigna Group pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Income Statement
- Analysis of Liquidity Ratios
- Analysis of Reportable Segments
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cigna Group for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Cigna Group, P/OP, long-term trends, calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Income from operations1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2007 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Cigna Group Annual Report.
- Share Price Trend
- The share price experienced significant fluctuations over the analyzed period. It started at $41.32 in early 2006, followed by an increase and subsequent volatility through 2009, reaching a low of $16.39 in that year. From 2010 onwards, there was a consistent upward trend, with the price rising from $33.87 in 2010 to a peak of $336.14 in early 2024. However, a decline is noted in the last recorded year, with the price decreasing to $302.92 in 2025.
- Operating Profit Per Share (OPPS) Development
- Data for operating profit per share begins from 2018, starting at $16.23. There was an initial decrease to $10.95 in 2019, followed by a strong recovery and steady growth each subsequent year. By 2025, OPPS reached $34.41, reflecting a substantial increase over the observed period, indicating improved operational profitability per share.
- Price to Operating Profit Ratio (P/OP)
- This ratio was available from 2018 onwards. It was highest at 15.94 in 2019, which corresponds to the year when operating profit per share was at its lowest within the recorded period, implying a relatively high share price compared to operating profit at that time. The ratio then declined to a low of 8.38 in 2020 and fluctuated moderately thereafter, ending at 8.8 in 2025. This decrease indicates that the share price grew at a slightly slower pace than operating profit per share, suggesting improved valuation relative to operating profitability.
- Overall Insights
- The data indicates a recovery and growth phase after a challenging period around 2009, reflected in share price trends. Operating profit per share, available from 2018, shows a positive trajectory, supporting the share price increase. The decreasing trend in the P/OP ratio following a peak in 2019 suggests enhanced operational efficiency or market reassessment of value, with the company potentially becoming more attractively priced relative to its earnings.
Comparison to Competitors
Cigna Group, P/OP, long-term trends, comparison to competitors
| Cigna Group | Abbott Laboratories | Intuitive Surgical Inc. | Medtronic PLC | UnitedHealth Group Inc. | |
|---|---|---|---|---|---|
| Feb 27, 2025 | |||||
| Feb 29, 2024 | |||||
| Feb 23, 2023 | |||||
| Feb 24, 2022 | |||||
| Feb 25, 2021 | |||||
| Feb 27, 2020 | |||||
| Feb 28, 2019 | |||||
| Feb 28, 2018 | |||||
| Feb 23, 2017 | |||||
| Feb 25, 2016 | |||||
| Feb 26, 2015 | |||||
| Feb 27, 2014 | |||||
| Feb 28, 2013 | |||||
| Feb 23, 2012 | |||||
| Feb 25, 2011 | |||||
| Feb 25, 2010 | |||||
| Feb 26, 2009 | |||||
| Feb 29, 2008 | |||||
| Feb 28, 2007 | |||||
| Feb 23, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).